Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)

PURPOSE: Optimal adjuvant chemotherapy for early-stage breast cancer balances efficacy and toxicity. We sought to determine whether single-agent paclitaxel (T) was inferior to doxorubicin and cyclophosphamide (AC), when each was administered for four or six cycles of therapy, and whether it offered...

Full description

Saved in:
Bibliographic Details
Main Authors: Shulman, Lawrence N., Berry, Donald A., Cirrincione, Constance T., Becker, Heather P., Perez, Edith A., O'Regan, Ruth, Martino, Silvana, Shapiro, Charles L., Schneider, Charles J., Kimmick, Gretchen, Burstein, Harold J., Norton, Larry, Muss, Hyman, Hudis, Clifford A., Winer, Eric P.
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2014
Subjects:
ORIGINAL REPORTS
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4105484/
https://ncbi.nlm.nih.gov/pubmed/24934787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.53.7142
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items